Biomerica, Inc. (BMRA) |
| 1.69 0 (0%) 07-13 16:00 |
| Open: | 1.67 |
| High: | 1.75 |
| Low: | 1.66 |
| Volume: | 6,627 |
| Market Cap: | 5(M) |
| PE Ratio: | -1.23 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 2.32 |
| Resistance 1: | 2.06 |
| Pivot price: | 1.74 |
| Support 1: | 1.63 |
| Support 2: | 1.36 |
| 52w High: | 4.6 |
| 52w Low: | 1.64 |
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
| EPS | -1.610 |
| Book Value | 1.100 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.061 |
| Profit Margin (%) | -96.46 |
| Operating Margin (%) | -131.51 |
| Return on Assets (ttm) | -54.6 |
| Return on Equity (ttm) | -94.3 |
Thu, 18 Jun 2026
Biomerica Inc (BMRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Thu, 28 May 2026
BMRA Q1 2026 Earnings: Loss of $0.44 Per Share Amid No Revenue Disclosure - Guidance Upgrade Report - Bölüm Sonu Canavarı
Wed, 27 May 2026
BMRA - Biomerica Inc Stock Price and Quote - Finviz
Fri, 22 May 2026
BMRA Q1 2026 Earnings: Biomerica Reports Net Loss of $0.44 Per Share Amid Ongoing Development Efforts - Earnings Beat Streak - dars.gov.et
Thu, 22 May 2025
Biomerica Reports Real-World Data Showing 49% Reduction in IBS S - GuruFocus
Wed, 16 Apr 2025
Biomerica (BMRA) Announces 1-for-8 Reverse Stock Split Effective - GuruFocus
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |